Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: A. D. Struthers
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• CKD stage 3

• Echo LVH

Exclusion Criteria:

• Known heart failure

• Patients already on Allopurinol

• Patients with gout

• Patients with hepatic disease

• Contraindications to MRI, including severe claustrophobia

• Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine

• Malignancy or other life threatening disease

• Pregnancy or lactating women

• Patients unable to provide written consent